1. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study 
Hood Thabit, MD, Alexandra Lubina-Solomon, PhD, Marietta Stadler, PhD, Lalantha Leelarathna, PhD, Emma Walkinshaw, MRCP, Andrew Pernet, RN, Janet M Allen, RN, Ahmed Iqbal, MRCP, Pratik Choudhary, MD, Kavita Kumareswaran, PhD, Marianna Nodale, MSc, Chloe Nisbet, BMedSci, Malgorzata E Wilinska, PhD, Katharine D Barnard, PhD, Prof David B Dunger, MD, Prof Simon R Heller, FRCP, Prof Stephanie A Amiel, FRCP, Mark L Evans, FRCP, Dr Roman Hovorka, PhD 
The Lancet Diabetes & Endocrinology 
Volume 2, Issue 9, Pages (September 2014)
DOI: /S (14)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial design *Compliance assessed.
The Lancet Diabetes & Endocrinology 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2
Trial profile
The Lancet Diabetes & Endocrinology 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3
Median (IQR) of sensor glucose (A) and insulin delivery (B) during closed loop and control period for the 24 h duration
Solid red line and red shaded area signify closed loop; dashed black line and peach shaded area signify control. The glucose range 3·9–8·0 mmol/L is denoted in panel A by horizontal black lines.
The Lancet Diabetes & Endocrinology 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

5. Figure 4
Individual values of time when glucose was in target glucose range of 3·9–8·0 mmol/L (A) and mean overnight glucose (B)
The Lancet Diabetes & Endocrinology 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions